FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293235235> ?p ?o ?g. }

• W4293235235 endingPage "416" @default.
• W4293235235 startingPage "403" @default.
• W4293235235 abstract "Background: Sodium-glucose cotransporter-2 (SGLT-2) inhibitor dapagliflozin is a novel antihyperglycemic drug that has cardioprotective effects. It has been shown to minimize the incidence of cardiovascular mortality and heart failure (HF) hospitalization. Furthermore, these benefits may remain regardless of the existence of diabetes. However, the mechanisms by which dapagliflozin mediates these effects in HF patient are unknown, and its efficacy and practical use are still debatable. Objectives: to assess the therapeutic effect of dapagliflozin on rat with experimentally induced HF and its possible underlying mechanism of action. Methods: The left anterior descending (LAD) coronary artery was ligated in rats to induce HF. Dapagliflozin (1 mg/kg/day) was given by gavage for four weeks. Heart weight (HW), Body weight (BW), blood pressure, heart rate (HR), fasting serum glucose, insulin, glycated hemoglobin A1C (HbA1c), cardiac injury markers [creatine kinase-MB (CK-MB), cardiac troponin I (cTnI), lactate dehydrogenase (LDH)], markers of fibrosis [transforming growth factor beta 1 (TGF-β1), procollagen I C-terminal propeptide (PICP), procollagen III N-terminal peptide (PIIINT)], mediators of inflamation [tumor necrosis factor-alpha (TNF-α)], markers of oxidative stress [super oxide dismutase (SOD) and malondialdehyde (MDA)] and mediators of apoptosis (caspase 3 and BCL-2) were assessed. Histopathological examinations were performed using hematoxylin and eosin (H & E) for the heart, lung, and liver, and masson trichrome for heart. Results: Dapagliflozin decreased HW, HW/BW, cardiac injury markers, markers of fibrosis, mediators of inflammation, MDA and cardiac level of Caspase 3, while increased levels of SOD and BCL-2 in HF-induced rats. Dapagliflozin also improved the histopathological picture of heart, liver and lung. Conclusion: Dapagliflozin attenuated fibrosis, inflammation, oxidative stress, and apoptosis in HF-induced rats, thereby alleviating myocardial remodeling and dysfunction. Dapagliflozin alleviated histopathological changes in the hearts, lungs, and livers." @default.
• W4293235235 created "2022-08-27" @default.
• W4293235235 creator A5008618734 @default.
• W4293235235 creator A5034693709 @default.
• W4293235235 creator A5063584171 @default.
• W4293235235 creator A5080223999 @default.
• W4293235235 date "2022-04-22" @default.
• W4293235235 modified "2023-09-27" @default.
• W4293235235 title "Dapagliflozin Treatment Improves Cardiac Remodeling and Dysfunction in Heart Failure Induced Rats" @default.
• W4293235235 doi "https://doi.org/10.14704/nq.2022.20.4.nq22138" @default.
• W4293235235 hasPublicationYear "2022" @default.
• W4293235235 type Work @default.
• W4293235235 citedByCount "0" @default.
• W4293235235 crossrefType "journal-article" @default.
• W4293235235 hasAuthorship W4293235235A5008618734 @default.
• W4293235235 hasAuthorship W4293235235A5034693709 @default.
• W4293235235 hasAuthorship W4293235235A5063584171 @default.
• W4293235235 hasAuthorship W4293235235A5080223999 @default.
• W4293235235 hasConcept C115725540 @default.
• W4293235235 hasConcept C126322002 @default.
• W4293235235 hasConcept C134018914 @default.
• W4293235235 hasConcept C2777180221 @default.
• W4293235235 hasConcept C2777420927 @default.
• W4293235235 hasConcept C2777422806 @default.
• W4293235235 hasConcept C2778198053 @default.
• W4293235235 hasConcept C2780559512 @default.
• W4293235235 hasConcept C500558357 @default.
• W4293235235 hasConcept C555293320 @default.
• W4293235235 hasConcept C71924100 @default.
• W4293235235 hasConceptScore W4293235235C115725540 @default.
• W4293235235 hasConceptScore W4293235235C126322002 @default.
• W4293235235 hasConceptScore W4293235235C134018914 @default.
• W4293235235 hasConceptScore W4293235235C2777180221 @default.
• W4293235235 hasConceptScore W4293235235C2777420927 @default.
• W4293235235 hasConceptScore W4293235235C2777422806 @default.
• W4293235235 hasConceptScore W4293235235C2778198053 @default.
• W4293235235 hasConceptScore W4293235235C2780559512 @default.
• W4293235235 hasConceptScore W4293235235C500558357 @default.
• W4293235235 hasConceptScore W4293235235C555293320 @default.
• W4293235235 hasConceptScore W4293235235C71924100 @default.
• W4293235235 hasIssue "4" @default.
• W4293235235 hasLocation W42932352351 @default.
• W4293235235 hasOpenAccess W4293235235 @default.
• W4293235235 hasPrimaryLocation W42932352351 @default.
• W4293235235 hasRelatedWork W2425826669 @default.
• W4293235235 hasRelatedWork W2809530260 @default.
• W4293235235 hasRelatedWork W2912308947 @default.
• W4293235235 hasRelatedWork W3007081498 @default.
• W4293235235 hasRelatedWork W3010787211 @default.
• W4293235235 hasRelatedWork W3020836689 @default.
• W4293235235 hasRelatedWork W3031055157 @default.
• W4293235235 hasRelatedWork W3141307700 @default.
• W4293235235 hasRelatedWork W3204564439 @default.
• W4293235235 hasRelatedWork W4281732677 @default.
• W4293235235 hasVolume "20" @default.
• W4293235235 isParatext "false" @default.
• W4293235235 isRetracted "false" @default.
• W4293235235 workType "article" @default.